AMGEN

Amgevita (adalimumab) (Amgen) (November-2020)Avsola® (infliximab) (Amgen) (March-2020)Kanjinti® (trastuzumab) (Amgen) (February-2020)Mvasi® (bevacizumab) (Amgen) (October-2018)Wezlana (ustekinumab) (Amgen) (December-2023)

Biosimilars Approved In The E.U.

Amgevita / Solymbic (adalimumab) (Amgen) (March-2017)Bekemv (eculizumab) (Amgen) (April-2023) Kanjinti® (trastuzumab) (Amgen / Allergan) (May-2018)Mvasi® (bevacizumab) (Amgen/Allergan) (January-2018)Wezenla (ustekinumab) (Amgen) (June-2024)

Biosimilars Approved In Australia

Amgevita (adalimumab) (Amgen) (November-2017) Kanjinti® (trastuzumab) (Amgen) (May-2019)Mvasi® (bevacizumab) (Amgen) (November-2019)Wezlana (ustekinumab) (Amgen) (January-2024)

Inter Partes Review Proceedings

ENBRELIPR2015-01792
IPR2017-01916
IPR2017-02066
HUMIRA / AMJEVITAIPR2015-01514
IPR2015-01517
NEULASTA / STIMUFENDIPR2019-00971
IPR2019-01183
IPR2020-00314
NEUPOGEN / NEULASTA / GRASTOFIL / LAPELGAIPR2016-01542
NEUPOGEN / NEULASTA / NIVESTYM / NYVEPRIAIPR2021-00528
NEUPOGEN / NEULASTA / PEGFILGRATIM (LUPIN)IPR2021-00326
NEUPOGEN / NEULASTA / RELEUKO / FYLNETRAIPR2019-00791
IPR2019-00797
NEUPOGEN / NEULASTA / RELEUKO / GRASTOFIL / LAPELGA / FYLNETRAPGR2019-00001
NEUPOGEN / NEULASTA / STIMUFENDIPR2019-01183
SOLIRIS / BKEMVIPR2019-00739
IPR2019-00740
IPR2019-00741

U.S. Patent Litigations

BLINCYTO1:22-cv-00035 (D. Del.)
DUPIXENT1:17-cv-10465 (D. Mass.)
2:17-cv-02613 (C.D. Cal.)
ENBREL1:09-cv-00805 (D. Del.)
2:16-cv-01118 (D.N.J.)
2:19-cv-11755 (D.N.J.)
3:13-cv-02904 (N.D. Cal.)
EVENITY1:23-cv-10861 (D. Mass.)
NEUPOGEN0:15-cv-62081 (S.D. Fla.)
0:18-cv-61828 (S.D. Fla.)
1:10-cv-01540 (E.D. Ill.)
1:18-cv-01064 (D. Del.)
1:20-cv-00561 (D. Del.)
2:13-cv-04911 (D.N.J.)
2:18-cv-03347 (D.N.J.)
3:14-cv-04741 (N.D. Cal.)
3:19-cv-00977 (N.D. Cal.)
3:19-cv-01374 (S.D. Cal.)
REPATHA1:14-cv-01317 (D. Del.)
1:14-cv-01349 (D. Del.)
1:14-cv-01393 (D. Del.)
1:14-cv-01414 (D. Del.)
2:21-cv-01816 (C.D. Cal.)
AMJEVITA / YUSIMRY1:19-cv-00139 (D. Del.)
AVASTIN / MVASI1:17-cv-00165 (D. Del.)
1:17-cv-01407 (D. Del.)
1:17-cv-01471 (D. Del.)
1:19-cv-00602 (D. Del.)
2:17-cv-07349 (C.D. Cal.)
AVASTIN / MVASI / GENENTECH CABILLY1:17-cv-01407 (D. Del.)
1:17-cv-01471 (D. Del.)
1:19-cv-00602 (D. Del.)
2:17-cv-07349 (C.D. Cal.)
ENBREL / ERELZI2:16-cv-01118 (D.N.J.)
3:13-cv-02904 (N.D. Cal.)
ENBREL / ETICOVO2:19-cv-11755 (D.N.J.)
EPOGEN / PROCRIT / RETACRIT1:15-cv-00839 (D. Del.)
EYLEA / PAVBLU1:24-cv-00039 (N.D.W. Va.) (transferred from 1:24-cv-00264 (C.D. Cal.)) / MDL 1:24-md-03103 (N.D.W. Va.)
GRANIX / NEUPOGEN / NEULASTA2:13-cv-04911 (D.N.J.)
HERCEPTIN / KANJINTI / GENENTECH CABILLY1:18-cv-00924 (D. Del.)
HUMIRA / AMJEVITA1:16-cv-00666 (D. Del.)
NEULASTA / FULPHILA2:17-cv-01235 (W.D. Pa.)
NEULASTA / LAPELGA0:15-cv-61631 (S.D. Fla.)
NEULASTA / NYVEPRIA1:20-cv-00201 (D. Del.)
NEULASTA / UDENYCA1:17-cv-00546 (D. Del.)
56-2017-00493553-CU-BT-VTA (CA Sup. Ct.)
NEULASTA / ZIEXTENZO2:16-cv-01276 (D.N.J.)
3:16-cv-02581 (N.D. Cal.)
3:19-cv-00977 (N.D. Cal.)
NEUPOGEN / GRASTOFIL0:15-cv-62081 (S.D. Fla.)
NEUPOGEN / NEULASTA / GRASTOFIL / LAPELGA0:18-cv-61828 (S.D. Fla.)
NEUPOGEN / NIVESTYM1:18-cv-01064 (D. Del.)
1:20-cv-00561 (D. Del.)
NEUPOGEN / NYPOZI3:19-cv-01374 (S.D. Cal.)
NEUPOGEN / RELEUKO2:18-cv-03347 (D.N.J.)
NEUPOGEN / ZARXIO3:14-cv-04741 (N.D. Cal.)
3:19-cv-00977 (N.D. Cal.)
NEUPOGEN / ZARXIO / NEULASTA / ZIEXTENZO3:19-cv-00977 (N.D. Cal.)
PRALUENT / REPATHA1:14-cv-01317 (D. Del.)
1:14-cv-01349 (D. Del.)
1:14-cv-01393 (D. Del.)
1:14-cv-01414 (D. Del.)
PROLIA / XGEVA / CT-P411:24-cv-06497 (D.N.J.)
PROLIA / XGEVA / FKS5181:24-cv-09555 (N.D. Ill.)
PROLIA / XGEVA / INTP235:24-cv-00642 (E.D.N.C.)
PROLIA / XGEVA / JUBBONTI / WYOST1:23-cv-02406 (D.N.J.)
PROLIA / XGEVA / SB161:24-cv-08417 (D.N.J.)
STELARA / WEZLANA1:22-cv-01549 (D. Del.)